Thank you.

This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.

Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.

User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.

Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.

Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population

BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.

A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.

BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.

Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.